Study of How Food and Other Medicines Affect MK-8527 in Healthy Adults Ages 18 to 55

What this Trial Is About

Researchers are studying a medicine called MK-8527 to understand how it behaves in the bodies of healthy adults aged 18 to 55. The study aims to learn how MK-8527 interacts when taken with food or combined with other medicines like probenecid and itraconazole. The goal is also to assess the safety of MK-8527 and whether participants can tolerate it without needing to stop due to health issues. Participants will receive single doses of MK-8527 under different conditions with food and without food, alone and combined with probenecid, and alone and combined with itraconazole. This crossover study allows each participant to experience all these dosing scenarios to compare how the medicine behaves in each case. During the study, participants will be monitored through blood and urine tests at specified times up to 336 hours after dosing to measure MK-8527 levels and its clearance. Researchers will also track any side effects or reasons for stopping treatment over approximately 43 days. The study is conducted by Merck Sharp & Dohme LLC and is expected to complete in October 2026.

A Clinical Study of MK-8527 in Healthy Participants (MK-8527-021)